AstraZeneca announced positive results from late-stage clinical trials for a drug treating chronic lung disease, with the pharmaceutical company's shares rising 4% following the news.

The trials demonstrated that the experimental treatment successfully reduced flare-ups in patients with chronic lung disease. The results represent a potential breakthrough in an area where other pharmaceutical companies have previously faced setbacks.

The positive trial outcome comes as a surprise to industry observers, given the challenging track record of similar treatments developed by rival companies in this therapeutic area. Previous attempts by competitors to develop effective treatments for this condition have encountered significant obstacles.

AstraZeneca's stock price increased by 4% in response to the trial results, reflecting investor optimism about the drug's commercial potential. The pharmaceutical company has not yet disclosed detailed data from the trials or provided a timeline for regulatory submission.

The development adds to AstraZeneca's portfolio of respiratory treatments and could represent a significant market opportunity if the drug receives regulatory approval. Further details about the trial methodology and patient outcomes are expected to be released at upcoming medical conferences.